So this seems to be the rally we were looking for but that is assuming it does not fade in the afternoon like every other recent rally attempt. So far the rally is a little more broad based and stronger but we have seen this story before. That being said even if this is the […]
March 10 Biotech Update- Do Not Underestimate CNAT
The sector seems to be searching for a bottom and it is not clear whether this is simply part of that process or a pause before the next leg down. As I noted last week, I will not try to call the bottom but will be a buyer on the large moves down. Whether this […]
Upcoming events for Pfizer
Pfizer (PFE) isn’t traditionally on my watchlist as a name to follow, however, this may be an exception. Palbocicib is likely the most exciting pipeline product in development at Pfizer right now. It received Breakthrough Therapy designation from the FDA in April 2013 for the treatment of breast cancer, following very encouraging Phase 2 results […]
March 7 Biotech Update- Selling Feeding Selling
I am going to spend today talking about the sector in general and send this note out early in light of the significant sell off that started yesterday afternoon and continued this morning. While the bulk of the discussion seemed to center on GILD it should be noted that it was the sector that got […]
Week’s Option Activity (2/20 ~ 3/04)
The following stocks had notable activity in their options during the past week(s): $CYTK (2/20): There were two large trades – one bullish and one bearish. (1) Bullish: 2,900 MAY risk reversals were purchased (stock at $9.85) for net 1.10 or total net cost of $319,000 (2,900 MAY 7.50 Strike Puts were sold for 1.90 […]
February 25 Biotech Update- Some Upcoming Catalysts
It is another day with the sector trading basically in line with market and the real outperformers/underperformers have news associated with them. At this point the real tension in the sector is between the clear continuation of the rally and the fear/expectation of a larger macro correction that will take the sector down with it. […]
February 17 Biotech Update- A Presidents Day Bonus
The market is obviously closed today but I wanted to have a brief note because I am not sure I will have time to write anything significant tomorrow. 1. One question that has been in the back of my mind is M&A. I keep expecting to see more as BMY, GILD, PFE, and others have […]
January 29- Biotech Update
Would you believe another snow day in Louisiana, which is number three in the past couple of weeks (if you were counting). In general, despite a very weak market , biotechs did fairly well, although it was the large caps holding up the sector with the small caps more mixed. It was nice to see […]
Upcoming Phase 3 trials
With a fresh start to 2014 and the biotech market still very strong, we wanted to examine some upcoming Phase 3 results that will be in focus in the first quarter. Expectations for some of these trials varies widely. We have a blend of small biotech to big pharma. Company: Merck (MRK) and Amgen (AMGN) […]
October 29- EOD
Well, it seemed like an odd day for the sector in that it was almost directionless. This is not to say that there were not moves among individual stocks but we are finally starting to see them move on merit and less on sector sentiment. I think this is a good sign and hopefully we […]
September 30-EOD
There was certainly some interesting news and action today. The market was weak early but biotech was much more mixed than one would have expected. It is good to see those pockets of strength during the broad market sell offs. 1. ARIA was interesting on two levels: AP113 data and Iclusig sales. There was additional […]
September 30-EOD
There was certainly some interesting news and action today. The market was weak early but biotech was much more mixed than one would have expected. It is good to see those pockets of strength during the broad market sell offs. 1. ARIA was interesting on two levels: AP113 data and Iclusig sales. There was additional […]
September 30-EOD
There was certainly some interesting news and action today. The market was weak early but biotech was much more mixed than one would have expected. It is good to see those pockets of strength during the broad market sell offs. 1. ARIA was interesting on two levels: AP113 data and Iclusig sales. There was additional […]
September 27- EOD
Not a particularly news rich day but the sector seemed to continue its momentum from yesterday and seemed to outperform the general market with a lot of green on a red day. 1. Well, it looks like JNJ is tossing another wrench in ECYT trials with more doxil supply problems. ECYT noted that they have […]
July 29- EOD
We finally had a major biotech merger but it was not one that got people excited as volumes and price action in biotech were neutral to negative for most of the day. Despite the lack of enthusiasm this was actually a pretty interesting day from the news front, so I will quickly touch on a […]
July 16- EOD
Seemed like a slow news day as the markets pulled back to consolidate some of the recent moves. Biotechs were not immune to the move, although some clearly performed better than others. 1. EPZM has shown incredible strength since the IPO. While I like this company’s technology and would like to own some shares, it […]
July 15- EOD
Well, there was not a lot of news out there in biotech land but oddly there is a lot I want to talk about and will work through it over the next couple of days. 1. ARIA Iclusig prescriptions came in weak again with new prescriptions down 26% and only a 9% gain in continuing […]
July 1- EOD
Today was the fallout of the AMGN bid for ONXX. There are a couple of aspects of it that I want to touch on and go a little further than my article this morning. 1. In my article I tried to cover the companies that I thought had the most compelling reasons to be interested […]
June 7- EOD
[This was meant to be posted Friday afternoon but did not seem to go through, so you get a bonus EOD of today] I do not think there is not much out there to add from today. I will touch on a couple of themes but it was generally a bounce back day for the […]
May 21 – End Of Day Biotech Wrap-up
Perhaps it is the start of the summer season but the market seems to have been quite the past couple of days or perhaps I am simply looking at the wrong parts of the market. 1. There were a number of EHA abstracts released today for PCYC and perhaps one of the most important was […]
